DERMAPHARM HOLDING SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.3 EUR | +0.81% |
|
-1.88% | -26.07% |
| 04-04 | DERMAPHARM : Berenberg keeps its Buy rating | ZD |
| 03-28 | Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 1.17B 1.25B 99.82B | Sales 2025 * | 1.22B 1.3B 104B | Capitalization | 1.69B 1.8B 144B |
|---|---|---|---|---|---|
| Net income 2024 * | 112M 120M 9.59B | Net income 2025 * | 130M 139M 11.13B | EV / Sales 2024 * | 2.14 x |
| Net Debt 2024 * | 812M 868M 69.49B | Net Debt 2025 * | 699M 747M 59.81B | EV / Sales 2025 * | 1.95 x |
| P/E ratio 2024 * |
15
x | P/E ratio 2025 * |
13
x | Employees | 3,497 |
| Yield 2024 * |
3.36% | Yield 2025 * |
3.84% | Free-Float | 32.26% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.81% | ||
| 1 week | -1.88% | ||
| Current month | -4.11% | ||
| 1 month | -6.62% | ||
| 3 months | -20.48% | ||
| 6 months | -15.45% | ||
| Current year | -26.07% |
1 week
30.80
33.10
1 month
30.8034.16
Current year
30.8043.22
1 year
30.8049.48
3 years
30.8091.95
5 years
28.0691.95
10 years
21.5891.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/07/17 | |
| Director of Finance/CFO | - | 31/10/22 | |
Britta Hamberger
IRC | Investor Relations Contact | - | 30/11/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 31/12/17 | |
Wilhelm Beier
CHM | Chairman | 68 | 31/07/17 |
Erwin Kern
BRD | Director/Board Member | 63 | 31/07/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.01% | 125 M€ | -.--% | ||
| 0.73% | 17 M€ | -.--% | - | |
| 0.16% | 79 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 31.3 | +0.81% | 38,113 |
| 25/04/24 | 31.05 | -1.43% | 22,157 |
| 24/04/24 | 31.5 | -3.08% | 34,510 |
| 23/04/24 | 32.5 | -0.61% | 22,522 |
| 22/04/24 | 32.7 | +2.51% | 32,788 |
Delayed Quote Xetra, April 26, 2024 at 04:35 pm
More quotes
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.3
EUR
Average target price
56.9
EUR
Spread / Average Target
+81.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.07% | 1.8B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DMP Stock
